Atara Biotherapeutics to Participate in Cell Therapy Panel Discussion at the Cowen 44th Annual Health Care Conference
February 28 2024 - 3:30PM
Business Wire
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell
immunotherapy, leveraging its novel allogeneic Epstein-Barr virus
(EBV) T-cell platform to develop transformative therapies for
patients with cancer and autoimmune diseases, today announced that
Pascal Touchon, President and Chief Executive Officer, will
participate in a cell therapy panel discussion at the Cowen 44th
Annual Health Care Conference on Wednesday, March 6, 2024 at 6:10
a.m. PST / 9:10 a.m. EST.
A live webcast of the presentation will be available by visiting
the Investors and Media section of atarabio.com. An archived replay
of the webcast will be available on the Company's website for 30
days following the live presentation.
About Atara Biotherapeutics, Inc.
Atara is harnessing the natural power of the immune system to
develop off-the-shelf cell therapies for difficult-to-treat cancers
and autoimmune conditions that can be rapidly delivered to patients
within days. With cutting-edge science and differentiated approach,
Atara is the first company in the world to receive regulatory
approval of an allogeneic T-cell immunotherapy. Our advanced and
versatile Epstein-Barr virus (EBV) T-cell platform does not require
T-cell receptor or HLA gene editing and forms the basis of a
diverse portfolio of investigational therapies that target EBV, the
root cause of certain diseases, in addition to next-generation
AlloCAR-Ts designed for best-in-class opportunities across a broad
range of hematological malignancies and B-cell driven autoimmune
diseases. Atara is headquartered in Southern California. For more
information, visit atarabio.com and follow @Atarabio on X and
LinkedIn.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240228404331/en/
Investor and Media Relations: Jason Awe, Ph.D. Senior
Director, Corporate Communications & Investor Relations (805)
217-2287 jawe@atarabio.com
Atara Biotherapeutics (NASDAQ:ATRA)
Historical Stock Chart
From Jan 2025 to Feb 2025
Atara Biotherapeutics (NASDAQ:ATRA)
Historical Stock Chart
From Feb 2024 to Feb 2025
